Title

COVID-19 in teriflunomide-treated patients with multiple sclerosis

UMMS Affiliation

Department of Neurology

Publication Date

2020-06-03

Document Type

Article

Disciplines

Health Services Administration | Immune System Diseases | Immunotherapy | Infectious Disease | Nervous System Diseases | Virus Diseases

Abstract

The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.

Keywords

Antiviral, COVID-19, Coronavirus, Multiple sclerosis, Teriflunomide

DOI of Published Version

10.1007/s00415-020-09944-8

Source

Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Jun 3:1–7. doi: 10.1007/s00415-020-09944-8. Epub ahead of print. PMID: 32494856; PMCID: PMC7268971. Link to article on publisher's site

Journal/Book/Conference Title

Journal of neurology

Related Resources

Link to Article in PubMed

PubMed ID

32494856

Share

COinS